Cargando…
Cardiovascular Effects in Childhood Cancer Survivors Treated with Anthracyclines
Anthracyclines are commonly used to treat childhood leukemias and lymphomas, as well as other malignancies, leading to a growing population of long-term childhood cancer survivors. However, their use is limited by cardiotoxicity, increasing survivors' vulnerability to treatment-related complica...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
SAGE-Hindawi Access to Research
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3038566/ https://www.ncbi.nlm.nih.gov/pubmed/21331374 http://dx.doi.org/10.4061/2011/134679 |
_version_ | 1782198113459503104 |
---|---|
author | Franco, Vivian I. Henkel, Jacqueline M. Miller, Tracie L. Lipshultz, Steven E. |
author_facet | Franco, Vivian I. Henkel, Jacqueline M. Miller, Tracie L. Lipshultz, Steven E. |
author_sort | Franco, Vivian I. |
collection | PubMed |
description | Anthracyclines are commonly used to treat childhood leukemias and lymphomas, as well as other malignancies, leading to a growing population of long-term childhood cancer survivors. However, their use is limited by cardiotoxicity, increasing survivors' vulnerability to treatment-related complications that can markedly affect their quality of life. Survivors are more likely to suffer from heart failure, coronary artery disease, and cerebrovascular accidents compared to the general population. The specific mechanisms of anthracycline cardiotoxicity are complex and remain unclear. Hence, determining the factors that may increase susceptibility to cardiotoxicity is of great importance, as is monitoring patients during and after treatment. Additionally, treatment and prevention options, such as limiting cumulative dosage, liposomal anthracyclines, and dexrazoxane, continue to be explored. Here, we review the cardiovascular complications associated with the use of anthracyclines in treating malignancies in children and discuss methods for preventing, screening, and treating such complications in childhood cancer survivors. |
format | Text |
id | pubmed-3038566 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | SAGE-Hindawi Access to Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-30385662011-02-17 Cardiovascular Effects in Childhood Cancer Survivors Treated with Anthracyclines Franco, Vivian I. Henkel, Jacqueline M. Miller, Tracie L. Lipshultz, Steven E. Cardiol Res Pract Review Article Anthracyclines are commonly used to treat childhood leukemias and lymphomas, as well as other malignancies, leading to a growing population of long-term childhood cancer survivors. However, their use is limited by cardiotoxicity, increasing survivors' vulnerability to treatment-related complications that can markedly affect their quality of life. Survivors are more likely to suffer from heart failure, coronary artery disease, and cerebrovascular accidents compared to the general population. The specific mechanisms of anthracycline cardiotoxicity are complex and remain unclear. Hence, determining the factors that may increase susceptibility to cardiotoxicity is of great importance, as is monitoring patients during and after treatment. Additionally, treatment and prevention options, such as limiting cumulative dosage, liposomal anthracyclines, and dexrazoxane, continue to be explored. Here, we review the cardiovascular complications associated with the use of anthracyclines in treating malignancies in children and discuss methods for preventing, screening, and treating such complications in childhood cancer survivors. SAGE-Hindawi Access to Research 2011-02-10 /pmc/articles/PMC3038566/ /pubmed/21331374 http://dx.doi.org/10.4061/2011/134679 Text en Copyright © 2011 Vivian I. Franco et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Franco, Vivian I. Henkel, Jacqueline M. Miller, Tracie L. Lipshultz, Steven E. Cardiovascular Effects in Childhood Cancer Survivors Treated with Anthracyclines |
title | Cardiovascular Effects in Childhood Cancer Survivors Treated with Anthracyclines |
title_full | Cardiovascular Effects in Childhood Cancer Survivors Treated with Anthracyclines |
title_fullStr | Cardiovascular Effects in Childhood Cancer Survivors Treated with Anthracyclines |
title_full_unstemmed | Cardiovascular Effects in Childhood Cancer Survivors Treated with Anthracyclines |
title_short | Cardiovascular Effects in Childhood Cancer Survivors Treated with Anthracyclines |
title_sort | cardiovascular effects in childhood cancer survivors treated with anthracyclines |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3038566/ https://www.ncbi.nlm.nih.gov/pubmed/21331374 http://dx.doi.org/10.4061/2011/134679 |
work_keys_str_mv | AT francoviviani cardiovasculareffectsinchildhoodcancersurvivorstreatedwithanthracyclines AT henkeljacquelinem cardiovasculareffectsinchildhoodcancersurvivorstreatedwithanthracyclines AT millertraciel cardiovasculareffectsinchildhoodcancersurvivorstreatedwithanthracyclines AT lipshultzstevene cardiovasculareffectsinchildhoodcancersurvivorstreatedwithanthracyclines |